The discovery of immune checkpoints, such as PD-1, CTLA-4, LAG-3, and TIM-3, has shifted the cancer treatment paradigm by targeting cancer itself to modulate a tumor-associated immune response. This evidence concerns the gene HAVCR2 and neoplasm.